CONTINUING EDUCATION TEST
Isolated anti-DFS70 autoantibodies: Negative disease correlation with a positive impact July 2019 [This form may be photocopied. It is no longer valid for CEUs after January 31 2021.)
TEST QUESTIONS Circles must be filled in, or test will not be graded. Shade circles like this: O Not like this: O
1. What laboratory test is a key diagnostic criterion for the diagnosis of systemic autoimmune rheumatic diseases (SARD)?
{a. immunoassay for autoantibodies {b. microarray testing {c. antinuclear autoantibodies (ANA) {d. all of the above
2. All of the following are considered diseases under the SARD category except
{a. osteoarthritis disease. {b. systemic lupus erythematosus. {c. mixed connective tissue disease. {d. Sjogren’s syndrome.
3. Which method is performed in the ANA test?
{a. direct immunofluorescence {b. indirect immunofluorescence {c. SPE {d. ELISA
4. Which substrate is used as the “gold standard” in the ANA screening test?
{a. HeLa cells {b. Le cells {c. HEp-1 cells {d. HEp-2 cells
5. The most popular ANA pattern encountered in screening is
{a. dense fine speckled. {b. speckled. {c. centromere. {d. nucleolar.
6. The autoantibodies to the DFS protein that confer cell protection by regulating transcription of stress-related genes is
{a. DFS75/LEDGFp70. {b. DFS70/LEDGFp70. {c. DFS71/LEDGFp75. {d. DFS70/LEDGFp75.
7. What committee has classified the challenging DFS pattern as AC-2?
{a. The International Consensus on ANA { Patterns
b. The National Consensus on ANA { Patterns
d. The World Health Organization {c. The International AC-2 Committee Tests can be taken online or by mail. Easy registration and payment options are available through NIU by following the links found at
www.mlo-online.com/ce. PLEASE PRINT CLEARLY NAME CITY PHONE STATE ZIP MAILING ADDRESS INSTITUTION/FACILITY E-MAIL ADDRESS
Send your $20 check payable to Northern Illinois University with this form to: University Outreach Services, Northern Illinois University, DeKalb, IL 60115-2860 Phone: 815-753-0031 FEE NOT REFUNDABLE OR TRANSFERABLE
P = Poor; E = Excellent
1. To what extent did the article focus on or clarify the objectives?
P E
2. To what extent was the article well-organized and readable?
P 16 JULY 2019
MLO-ONLINE.COM E
3. How will you use the CE units? state license
recertification
employment other
CE Licensure Information for FL and CA:
FL: Your FL license number:____________________ (required for CE credit)
CA: Accrediting Agency: 0001 (for use in submitting your CE credits to CA)
MLO and Northern Illinois University (NIU), DeKalb, IL, are co-sponsors in offering continuing education units (CEUs) for this issue’s CE article. CEUs or contact hours are granted by the College of Health and Human Sciences at Northern Illinois University, which has been approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® program. Approval as a provider of continuing education programs has been granted by the state of Florida (Provider No. JP0000496). Continuing education credits awarded for successful completion of this test are acceptable for the ASCP Board of Registry Continuing Competence Recognition Program. Readers who pass the test successfully (scoring 70% or higher) will receive a certificate for 1 contact hour of P.A.C.E.®
credit. Participants should allow three to five weeks for receipt of certificate. The fee for this continuing education test is $20. This test was prepared by Amanda Voelker, MPH, MT(ASCP), MLS, Clinical Education Coordinator, School of HealthStudies, Northern Illinois University, DeKalb, IL. HOME WORK
8. A positive DFS IFA result is confirmatory and does not need to have follow-up testing.
{a. True {b. False
9. The presence of DFS ANA and/or anti-DFS70 antibodies have been detected in patients with the following conditions, except
{a. healthy individuals. {b. individuals with psoriasis. {c. individuals with heart disease. {d. individuals with ocular diseases.
10. Anti-DFS70 in patients with SARD is typically accompanied by additional SARD-related antidbodies.
{a. True {b. False
11. According to a study in a Spanish cohort, the use of anti-DFS70 testing has saved the healthcare system approximately ______________ dollars.
{a. 10 thousand {b. 50 thousand {c. 70 thousand {d. 70 billion
12. Which healthcare system is one of the first facilities in the U.S. to acquire the use of the ICAP system?
{a. Mayo Clinic {b. Northwestern Medical Hospital {c. Cleveland Clinic {d. Lexington Medical Center
13. The lab at LMC often termed a high number of ANA patterns as ______________________ of uncertain significance, which is now classified as DFS with the ICAP designation.
{a. homogeneous {b. nucleolar {c. mixed speckled/homogeneous {d. mixed speckleld/nucleolar
14. What utility is used with patients who have a non-isolated DFS70 ANA and positive antigen specificities on an ENA panel to diagnose a SARD disease?
{a. clinical findings that support the ENA { antigen specificity d. none of the above
{a. computer-assisted microscopy and { hiring extra lab scientists
c. computer-assisted microscopy and { semi-automated slide preparation
16. What percentage of ANA’s with a DFS pattern show DFS70 ANA specificity?
{a. 10 percent {b. 20 percent {c. 30 percent {d. 40 percent
17. A six-test ENA pattern is sufficient enough to detect all possible ANA-related autoantibody specificities.
{a. True {b. False
18. What is useful to healthcare providers to effectively interpret results of ANA testing?
{a. computer-formatted templates that fit { individual patient results
c. specialty certification in autoimmune { diseases
{b. physician consults with immunologists d. the use of the internet
{c. immunoblot/immunoassay confirmation {b. molecular testing
15. What tools were utilized at the LMC lab to help manage significantly high volume of ANA testing?
b. semi-automated slide preparation and { the use of a reference lab d. the use of a reference lab
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72
